Department of Radiology
Found 11 results
Filters: Author is Carrasquillo, Jorge A  [Clear All Filters]
2019
Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, Zhang Z, Lyashchenko SK, Fung AM, Pentlow KS et al..  2019.  Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.. J Nucl Med. 60(12):1794-1801.
Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G et al..  2019.  Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.. J Nucl Med. 60(11):1517-1523.
O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G et al..  2019.  Pharmacokinetics and Biodistribution of a [Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.. Mol Pharm. 16(7):3083-3090.
2018
Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT et al..  2018.  ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.. Mol Pharm. 15(6):2133-2141.
2016
Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M et al..  2016.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.. J Nucl Med. 57(12):1858-1864.
Cheal SM, Xu H, Guo H-F, Lee S-G, Punzalan B, Chalasani S, Fung EK, Jungbluth A, Zanzonico PB, Carrasquillo JA et al..  2016.  Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.. Eur J Nucl Med Mol Imaging. 43(5):925-937.
2015
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AMak et al..  2015.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.. Clin Cancer Res. 21(23):5277-85.
2014
Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS.  2014.  Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.. J Nucl Med. 55(12):2045-9.
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gönen M et al..  2014.  ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.. Eur J Nucl Med Mol Imaging. 41(11):2093-105.
2013
E Ryan R, Sofocleous CT, Schöder H, Carrasquillo JA, Nehmeh S, Larson SM, Thornton R, Siegelbaum RH, Erinjeri JP, Solomon SB.  2013.  Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness.. Radiology. 268(1):288-95.
2011
Schoellnast H, Larson SM, Nehmeh SA, Carrasquillo JA, Thornton RH, Solomon SB.  2011.  Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.. Cardiovasc Intervent Radiol. 34 Suppl 2:S182-5.